Last updated: July 13, 2026
Value Drug Company v. Allergan Sales, LLC (1:16-cv-11744): Litigation Summary, Claims at Issue, and Patent/Generic Risk Read-Through
What happened in Value Drug Company v. Allergan Sales, LLC, 1:16-cv-11744?
Status and outcome: Sufficient case-record data is not available in the prompt to produce a complete, accurate litigation summary (claims asserted, parties’ positions, procedural posture, orders, trial dates, settlement terms, or final disposition).
What claims or patent rights did Value Drug Company allege against Allergan Sales?
No docket-level information is provided, so the patent(s) asserted, the type of IP at issue (Orange Book-listed patents, formulation patents, method-of-use patents, or device/other IP), and the asserted infringement theories cannot be stated accurately.
What is the procedural posture for 1:16-cv-11744 (motions, scheduling, discovery, trial dates)?
No filings, orders, hearing dates, or reporting milestones are included, so the litigation timeline cannot be constructed without risking factual errors.
Did Value Drug file a Paragraph IV or Hatch-Waxman-type challenge, and what FDA filing triggered the case?
The prompt does not identify the drug product, the Orange Book listing(s), the FDA application type (ANDA/BLA), the applicant(s), or whether the case is tied to a Paragraph IV certification. Without that, the nexus to FDA exclusivity and the generic entry risk cannot be analyzed.
How did Allergan respond (answer, invalidity, non-infringement, unenforceability)?
The record content is not included. Without Allergan’s answer or claim construction/invalidation posture, the litigation analysis cannot be made.
What did the court rule on key motions (dismissal, venue, claim construction, preliminary injunction, summary judgment)?
No orders or motion outcomes are included. Any statement about rulings, claim scope, or injunction likelihood would be speculative.
Was there a settlement, and what were the settlement terms affecting generic entry?
Settlement terms, effective dates, “carve-outs,” payment-for-delay provisions, launch-forcing triggers, and stipulated injunction provisions are not provided. A settlement analysis would be incomplete.
Which patents are implicated by this docket, and what is their expiration/last date of patent protection?
Patent numbers, listed Orange Book patents, expiration dates, and any terminal disclaimers are not provided. A protection-duration or exclusivity-loss timeline cannot be produced.
How many patents cover the relevant product and what is the strength profile for infringement vs. validity defenses?
No asserted-claim mapping, validity challenges, or damages/monetary theories are included, so patent estate strength cannot be quantified.
How does this case affect biosimilar or generic launch risk for the relevant Allergan product?
No product, indication, dosage form, or FDA pathway is specified. Launch-risk analysis cannot be tied to exclusivity/patent cliffs or to any specific generic/biosimilar applicant conduct.
What settlements or litigation outcomes in this case would matter for licensing, portfolio strategy, or investment decisions?
No discrete business outcomes (noninfringement finding, covenant not to sue, stipulated dismissal with/without prejudice, or licensing agreement) are included, so actionable conclusions cannot be derived.
Key Takeaways
The prompt does not contain the docket record, asserted patents, court orders, or outcome details required to produce an accurate litigation summary and analysis for Value Drug Company v. Allergan Sales, LLC (1:16-cv-11744).
FAQs
- What patents are typically asserted in Value Drug Company v. Allergan Sales, LLC 1:16-cv-11744?
- Was 1:16-cv-11744 resolved by settlement or adjudication on the merits?
- Did the case involve a Paragraph IV certification tied to an ANDA filing?
- What effect did any court injunction or dismissal have on generic launch timing?
- How would this docket impact freedom-to-operate for an ANDA filer targeting the same Allergan product?
References
No citations are provided in the prompt, and no reliable case-record source is included.
